Tissue | Expression Dynamics | Abbreviation |
Cervix | | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Skin | | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003158926 | Skin | cSCC | cell-substrate adhesion | 130/4864 | 363/18723 | 1.87e-05 | 2.23e-04 | 130 |
GO:000722924 | Skin | cSCC | integrin-mediated signaling pathway | 47/4864 | 107/18723 | 4.21e-05 | 4.43e-04 | 47 |
GO:007137518 | Skin | cSCC | cellular response to peptide hormone stimulus | 104/4864 | 290/18723 | 1.15e-04 | 1.06e-03 | 104 |
GO:1901653110 | Skin | cSCC | cellular response to peptide | 124/4864 | 359/18723 | 1.75e-04 | 1.49e-03 | 124 |
GO:000716024 | Skin | cSCC | cell-matrix adhesion | 85/4864 | 233/18723 | 2.43e-04 | 1.98e-03 | 85 |
GO:0032869110 | Skin | cSCC | cellular response to insulin stimulus | 75/4864 | 203/18723 | 3.53e-04 | 2.78e-03 | 75 |
GO:0032868110 | Skin | cSCC | response to insulin | 93/4864 | 264/18723 | 5.10e-04 | 3.83e-03 | 93 |
GO:001631115 | Skin | cSCC | dephosphorylation | 134/4864 | 417/18723 | 2.65e-03 | 1.50e-02 | 134 |
GO:000828616 | Skin | cSCC | insulin receptor signaling pathway | 43/4864 | 116/18723 | 5.44e-03 | 2.73e-02 | 43 |
GO:0150115112 | Thyroid | PTC | cell-substrate junction organization | 67/5968 | 101/18723 | 1.14e-12 | 5.23e-11 | 67 |
GO:000704420 | Thyroid | PTC | cell-substrate junction assembly | 62/5968 | 95/18723 | 2.28e-11 | 8.76e-10 | 62 |
GO:004804119 | Thyroid | PTC | focal adhesion assembly | 56/5968 | 87/18723 | 4.63e-10 | 1.48e-08 | 56 |
GO:0150116111 | Thyroid | PTC | regulation of cell-substrate junction organization | 48/5968 | 71/18723 | 6.71e-10 | 2.04e-08 | 48 |
GO:1901653111 | Thyroid | PTC | cellular response to peptide | 169/5968 | 359/18723 | 9.81e-10 | 2.89e-08 | 169 |
GO:0010810112 | Thyroid | PTC | regulation of cell-substrate adhesion | 113/5968 | 221/18723 | 1.87e-09 | 5.28e-08 | 113 |
GO:0031589111 | Thyroid | PTC | cell-substrate adhesion | 169/5968 | 363/18723 | 2.73e-09 | 7.57e-08 | 169 |
GO:0043434113 | Thyroid | PTC | response to peptide hormone | 188/5968 | 414/18723 | 4.13e-09 | 1.09e-07 | 188 |
GO:0051893111 | Thyroid | PTC | regulation of focal adhesion assembly | 44/5968 | 66/18723 | 6.73e-09 | 1.70e-07 | 44 |
GO:0090109111 | Thyroid | PTC | regulation of cell-substrate junction assembly | 44/5968 | 66/18723 | 6.73e-09 | 1.70e-07 | 44 |
GO:0071375110 | Thyroid | PTC | cellular response to peptide hormone stimulus | 136/5968 | 290/18723 | 5.49e-08 | 1.17e-06 | 136 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PTPRA | SNV | Missense_Mutation | rs758310508 | c.12G>T | p.Trp4Cys | p.W4C | P18433 | protein_coding | tolerated_low_confidence(0.1) | probably_damaging(0.99) | TCGA-A1-A0SP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | | SD |
PTPRA | SNV | Missense_Mutation | novel | c.2377G>C | p.Asp793His | p.D793H | P18433 | protein_coding | deleterious(0.04) | benign(0.25) | TCGA-A2-A0CL-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | SD |
PTPRA | SNV | Missense_Mutation | | c.2064G>T | p.Gln688His | p.Q688H | P18433 | protein_coding | tolerated(0.09) | benign(0.017) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
PTPRA | SNV | Missense_Mutation | rs138944640 | c.317C>T | p.Thr106Met | p.T106M | P18433 | protein_coding | deleterious_low_confidence(0) | benign(0.212) | TCGA-AR-A2LQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | docetaxel | SD |
PTPRA | SNV | Missense_Mutation | | c.742N>G | p.Leu248Val | p.L248V | P18433 | protein_coding | tolerated(0.05) | benign(0.122) | TCGA-C8-A26V-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | tamoxiphen | CR |
PTPRA | SNV | Missense_Mutation | novel | c.2060G>A | p.Arg687Gln | p.R687Q | P18433 | protein_coding | deleterious(0.01) | probably_damaging(0.943) | TCGA-E2-A15L-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
PTPRA | SNV | Missense_Mutation | | c.1763A>T | p.Tyr588Phe | p.Y588F | P18433 | protein_coding | deleterious(0.01) | probably_damaging(1) | TCGA-GM-A2DD-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | CR |
PTPRA | SNV | Missense_Mutation | novel | c.790N>A | p.Glu264Lys | p.E264K | P18433 | protein_coding | tolerated(0.29) | possibly_damaging(0.653) | TCGA-GM-A3XL-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | fluorouracil | CR |
PTPRA | insertion | Frame_Shift_Ins | novel | c.1686_1687insGGACACACTCCCTCCTA | p.Arg563GlyfsTer19 | p.R563Gfs*19 | P18433 | protein_coding | | | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
PTPRA | insertion | Frame_Shift_Ins | novel | c.1688_1689insATGCTGGAATCCC | p.Val564CysfsTer12 | p.V564Cfs*12 | P18433 | protein_coding | | | TCGA-A7-A0CE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |